Filing Flows › Bio-Rad Laboratories (BIO) › Stock forecast & fair value
Bio-Rad Laboratories (BIO) stock forecast and fair value
Bio-Rad Laboratories (BIO) trades at $381.57. 3 analysts' median price target is $335.00 (-12%), from $280.00 to $390.00. Across 23 valuation methods the middle fair value is $402.04 (+5%).
Fair value by method
| Method | Low | Point | High | vs price |
|---|---|---|---|---|
| P/E vs peers | $1,071.83 | $1,353.52 | $1,695.98 | +255% |
| P/E vs peers, weighted | $1,110.94 | $1,312.03 | $1,517.71 | +244% |
| EV/EBITDA vs peers | $83.61 | $100.70 | $114.53 | -74% |
| EV/EBITDA vs peers, weighted | $91.60 | $106.39 | $112.26 | -72% |
| EV/Sales vs peers | $292.00 | $673.02 | $731.16 | +76% |
| EV/Sales vs peers, weighted | $443.71 | $610.65 | $691.93 | +60% |
| EV/Sales vs peers, matched | $137.69 | $177.18 | $218.30 | -54% |
| Residual income | $311.06 | $322.77 | $335.16 | -15% |
| Sum of the parts (segments × peer EV/Sales) | $254.22 | $468.46 | $596.08 | +23% |
| Sum of the parts, weighted (segments × weighted peer EV/Sales) | $363.38 | $490.16 | $686.04 | +28% |
Bio-Rad Laboratories' latest quarter
Bio-Rad Laboratories, Q3 2026: revenue $656M (+0.5% year over year), operating margin -7.6%, net earnings $459M, operating cash flow $96.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for BIO stock?
The median of 3 analysts' 12-month targets is $335.00, -12% from $381.57; the range is $280.00 to $390.00. The average rating is hold.
What is Bio-Rad Laboratories' fair value?
The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between $100.70 and $1,353.52, with a middle value of $402.04 against a price of $381.57. Each method's assumptions are on the page.
Does Bio-Rad Laboratories usually beat earnings estimates?
It beat the consensus EPS estimate in 60% of the quarters on record.
Is BIO stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.